BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 24957754)

  • 1. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
    Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
    J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
    de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
    Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
    Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer.
    Chatzikonstantinou G; Keller C; Scherf C; Bathen B; Köhn J; Tselis N
    Brachytherapy; 2021; 20(1):44-49. PubMed ID: 32826171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
    Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.
    Hermesse J; Biver S; Jansen N; Lenaerts E; De Patoul N; Vynckier S; Coucke P; Scalliet P; Nickers P
    Strahlenther Onkol; 2009 Nov; 185(11):736-42. PubMed ID: 19899007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer.
    Dincer N; Ugurluer G; Mustafayev TZ; Serkizyan A; Aydin G; Güngör G; Yapici B; Atalar B; Özyar E
    Brachytherapy; 2024; 23(1):18-24. PubMed ID: 38000958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: Initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy.
    Kauffmann G; Wu T; Al-Hallaq H; Hasan Y
    Brachytherapy; 2017; 16(1):141-146. PubMed ID: 27866953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
    Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
    Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
    Dubouloz A; Rouzaud M; Tsvang L; Verbakel W; Björkqvist M; Linthout N; Lencart J; Pérez-Moreno JM; Ozen Z; Escude L; Zilli T; Miralbell R
    Radiat Oncol; 2018 Jun; 13(1):114. PubMed ID: 29921291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer.
    Spratt DE; Scala LM; Folkert M; Voros L; Cohen GN; Happersett L; Katsoulakis E; Zelefsky MJ; Kollmeier MA; Yamada Y
    Brachytherapy; 2013; 12(5):428-33. PubMed ID: 23622710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer.
    Yoshioka Y; Sasamura K; Ito M; Kaneko M; Takahashi T; Anno W; Shimoyachi N; Suzuki J; Okuda T; Kashihara T; Inaba K; Igaki H; Itami J
    Phys Imaging Radiat Oncol; 2023 Apr; 26():100445. PubMed ID: 37197153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.
    Kunogi H; Cunha JAM; Chang AJ; Gadzinski AJ; Shinohara K; Hsu IC
    Brachytherapy; 2017; 16(6):1113-1118. PubMed ID: 28869143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.
    Wahl M; Descovich M; Shugard E; Pinnaduwage D; Sudhyadhom A; Chang A; Roach M; Gottschalk A; Chen J
    Technol Cancer Res Treat; 2017 Apr; 16(2):178-187. PubMed ID: 27199276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.
    Kishan AU; Park SJ; King CR; Roberts K; Kupelian PA; Steinberg ML; Kamrava M
    Br J Radiol; 2015; 88(1056):20150658. PubMed ID: 26463234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma.
    Walter F; Nierer L; Rottler M; Duque AS; Weingandt H; Well J; Shpani R; Landry G; Seidensticker M; Streitparth F; Ricke J; Belka C; Corradini S
    Radiat Oncol; 2021 May; 16(1):86. PubMed ID: 33957941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing.
    Adams Q; Hopfensperger KM; Kim Y; Wu X; Xu W; Shukla H; McGee J; Caster JM; Flynn RT
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1543-1550. PubMed ID: 30092333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.